BlackRock Global Funds - World Healthscience Fund D2Register to Unlock Ratings |
Performance History | 30/09/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 11.3 | 16.1 | 7.5 | -2.9 | 8.0 | |
+/-Cat | -6.2 | 6.7 | 12.2 | 0.3 | 3.5 | |
+/-B’mrk | - | -2.1 | 1.7 | -0.3 | -0.3 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 08/10/2024 | USD 82.46 | |
Day Change | -0.15% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU0329593007 | |
Fund Size (Mil) 30/09/2024 | USD 14827.92 | |
Share Class Size (Mil) 08/10/2024 | USD 1425.05 | |
Max Initial Charge | 5.26% | |
Ongoing Charge 09/02/2023 | 1.07% |
Morningstar Research |
Analyst Report | 09/11/2023 Ramanand Kothari, Senior Analyst Morningstar, Inc |
A seasoned healthcare investor backed by a stable and well-resourced team underpins our conviction in BGF World Healthscience. The clean D share class retains its Morningstar Analyst Rating of Bronze, where other share classes range from Bronze... | |
Click here to read this analyst report on the underlying fund. |
Morningstar Pillars | |
---|---|
People | 24 |
Parent | 24 |
Process | 23 |
Performance | |
Price |
Investment Objective: BlackRock Global Funds - World Healthscience Fund D2 |
The Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance (“ESG”) investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Xiang Liu 01/06/2020 | ||
Erin Xie 01/04/2011 | ||
Inception Date 12/11/2007 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care NR USD | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BlackRock Global Funds - World Healthscience Fund D2 | 31/08/2024 |
|
|
Top 5 Holdings | Sector | % |
UnitedHealth Group Inc | Healthcare | 7.13 |
Eli Lilly and Co | Healthcare | 6.20 |
Novo Nordisk A/S Class B | Healthcare | 6.17 |
Boston Scientific Corp | Healthcare | 4.36 |
AbbVie Inc | Healthcare | 4.13 |
Increase Decrease New since last portfolio | ||
BlackRock Global Funds - World Healthscience Fund D2 |